Akeso and Summit notch another Phase III win with their Keytruda competitor
Akeso and Summit's drug previously beat Keytruda in a separate Phase III study, extending PFS by five months.
24 April 2025
24 April 2025
Akeso and Summit's drug previously beat Keytruda in a separate Phase III study, extending PFS by five months.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.